Best of Oncology West 2022 Conference


The Best of Oncology West 2022 Conference highlights the top 3-4 most clinically relevant achievements of 2021 for several tumour sites. Faculty will be drawn from some of the most influential oncologists across Canada. The Conference is chaired by Dr. Sharlene Gill and Dr. Daniel Heng and will incorporate several multi-disciplinary event sessions addressing: radiation oncology, surgical oncology and supportive care.

Learning Objectives:

1. To discuss the pivotal oncology trials presented in the different disease sites
2. To review the current standard of care for key malignancies
3. To discuss the current controversies in the management of specific cancers



Friday, January 14, 2022


8:30 am - 2:30 pm

Local Time

  • Timezone: America/New_York
  • Date: Friday, January 14, 2022
  • Time: 11:30 am - 5:30 pm


Registration will be complimentary for Healthcare Professionals and can be completed below.  Industry representatives (both sponsor and non-sponsor) can register by contacting Laura Davidson at

Book Event

1 Ticket selected.

Available Tickets: Unlimited

The ticket is sold out. You can try another ticket or another date.

Scientific Agenda

Times listed are in PST

8:30 am – 8:40 am

Welcome Address by Chairs – Dr. Sharlene Gill & Dr. Daniel Heng

8:40 am – 9:00 am 

Special Session: Molecular Genetics Testing 101 – Dr. Alexander Wyatt

9:00 am – 9:25 am

Prostate GU Cancer – Dr. Steven Yip

9:25 am – 9:45 am

Non-Prostate GU Cancer – Dr.Lucia Nappi

9:45 am – 10:05 am

Q&A Session – Dr. Steven Yip & Dr. Lucia Nappi

9:55 am – 10:05 am


10:05 am – 10:25 am

Gynecological Cancers – Dr. Yvette Drew

10:25 am – 10:45 am

Head & Neck – Dr. Nicole Chau

10:45 am – 11:10 am

Lung Cancer – Dr. Aliyah Pabani

11:10 am – 11:40 am


11:40 am – 12:25 pm

Pfizer-BMS Alliance Lunch Symposium: Thrombosis in Cancer – Dr. Agnes Lee

12:25 pm – 12:45 pm

Colorectal GI Cancer – Dr. Sharlene Gill

12:45 pm – 1:05 pm

Non-Colorectal GI Cancer – Dr. Hatim Karachiwala

1:05 pm – 1:15 pm


1:15 pm – 1:35 pm

Lymphoma – Dr. Kerry Savage

1:35 pm – 1:55 pm

Melanoma – Dr. Alison Weppler

1:55 pm – 2:20 pm

Breast Cancer – Dr. Nancy Nixon

2:20 pm – 2:30 pm

Closing Remarks by Chairs – Dr. Sharlene Gill & Dr. Daniel Heng

personAbout the Faculty

Dr. Sharlene Gill

Dr. Sharlene Gill

Conference Chair

Dr. Gill is a Professor of Medicine at the University of British Columbia and a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver. She received a Bachelor’s of Science in Pharmacy and an MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Master’s of Public Health from the Harvard School of Public Health. In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina. She is actively engaged in education and research, with over 100 peer-reviewed publications and book chapters to her credit. Dr. Gill currently serves as the Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee, and is President-Elect for the Canadian Association of Medical Oncologists.

Dr. Daniel Heng

Dr. Daniel Heng

Conference Chair

Dr. Heng is a Staff Medical Oncologist at the Tom Baker Cancer Center in Calgary, Alberta and a Clinical Professor of Medicine at the University of Calgary. He received his MD from the University of Calgary and completed his internal medicine and medical oncology residencies at the University of British Columbia in Vancouver, BC. He was trained at the BC Cancer Agency in Vancouver, Canada and then completed an Experimental Therapeutics fellowship at the Cleveland Clinic Taussig Cancer Institute. He received a Masters of Public Health from Harvard University. He is the Chair of the International mRCC Database Consortium (IMDC) which has created and validated the IMDC criteria (a.k.a. Heng Criteria) for prognostication in metastatic renal cell carcinoma patients. He is also the Chair of the Genitourinary Tumor Group in Calgary and Medical Leader for the Clinical Research Unit at the TBCC. He has a keen interest in outcomes, prognostic factors and clinical trials research in metastatic renal cell carcinoma and other genitourinary malignancies.


For sponsorship-related inquiries, please contact Bernadette Gregoris at


Phizer-BMS Alliance Logo


Astellas Logo
Pfizer logo
Ipsen Logo
Merck Logo


BMS Logo
Seagen Logo